Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Bamberg, K., Johansson, U., Edman, K., William-Olsson, L., Myhre, S., Gunnarsson, A., Geschwindner, S., Aagaard, A., Bjornson Granqvist, A., Jaisser, F., Huang, Y., Granberg, K.L., Jansson-Lofmark, R., Hartleib-Geschwindner, J.(2018) PLoS One 13: e0193380-e0193380
- PubMed: 29474466 
- DOI: 10.1371/journal.pone.0193380
- Primary Citation of Related Structures:  
5MWP, 5MWY - PubMed Abstract: 
Excess mineralocorticoid receptor (MR) activation promotes target organ dysfunction, vascular injury and fibrosis. MR antagonists like eplerenone are used for treating heart failure, but their use is limited due to the compound class-inherent hyperkalemia risk ...